BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
-13.87%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$1.07B
AUM Growth
+$1.07B
(-19%)
Cap. Flow
-$42.3M
Cap. Flow
% of AUM
-3.94%
Top 10 Holdings %
Top 10 Hldgs %
57.38%
Holding
61
New
4
Increased
17
Reduced
18
Closed
4
Top Buys
| 1 |
Xencor
XNCR
|
$50.5M |
| 2 |
Revolution Medicines
RVMD
|
$30.6M |
| 3 |
CytomX Therapeutics
CTMX
|
$24.2M |
| 4 |
AnaptysBio
ANAB
|
$10.6M |
| 5 |
Black Diamond Therapeutics
BDTX
|
$9.45M |
Top Sells
| 1 |
ARQL
Arqule Inc
ARQL
|
$59.5M |
| 2 |
Arcus Biosciences
RCUS
|
$49.1M |
| 3 |
Cytokinetics
CYTK
|
$38.5M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
$14.7M |
| 5 |
Ionis Pharmaceuticals
IONS
|
$11.1M |
Sector Composition
| 1 | Healthcare | 95.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
PRNB
1
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $94M | 8.76% | 1,583,595 -133,139 | -8% | -$7.91M |
|
|
2
Ionis Pharmaceuticals
IONS
$6.79B
| $91.9M | 8.57% | 1,944,517 -235,218 | -11% | -$11.1M |
|
3
AC Immune
ACIU
$205M
| $78.4M | 7.31% | 11,342,505 | – | – |
|
|
SWTX
4
DELISTED
SpringWorks Therapeutics
SWTX
| $74.7M | 6.96% | 2,767,630 -311,525 | -10% | -$8.41M |
|
5
Xoma
XOMA
$392M
| $56.4M | 5.26% | 2,773,385 +130,980 | +5% | +$2.67M |
|
|
6
Xencor
XNCR
$580M
| $50.5M | 4.7% | +1,689,300 | New | +$50.5M |
|
|
7
Cytokinetics
CYTK
$4.23B
| $46.4M | 4.33% | 3,938,280 -3,268,178 | -45% | -$38.5M |
|
8
Merus
MRUS
$4.98B
| $42.9M | 4% | 3,544,654 +375,000 | +12% | +$4.54M |
|
|
CALA
9
DELISTED
Calithera Biosciences, Inc
CALA
| $42.4M | 3.96% | 9,559,642 | – | – |
|
|
MTEM
10
DELISTED
Molecular Templates, Inc.
MTEM
| $37.9M | 3.53% | 2,850,271 -508,061 | -15% | -$6.75M |
|
|
11
Revolution Medicines
RVMD
$7.1B
| $30.6M | 2.86% | +1,398,070 | New | +$30.6M |
|
12
Xenon Pharmaceuticals
XENE
$2.98B
| $30.3M | 2.83% | 2,674,338 +725,263 | +37% | +$8.22M |
|
|
13
CytomX Therapeutics
CTMX
$336M
| $30.1M | 2.8% | 3,921,973 +3,155,825 | +412% | +$24.2M |
|
14
Kura Oncology
KURA
$686M
| $24.2M | 2.26% | 2,434,696 +436,420 | +22% | +$4.34M |
|
|
15
AnaptysBio
ANAB
$569M
| $23.9M | 2.23% | 1,690,237 +750,672 | +80% | +$10.6M |
|
16
Syndax Pharmaceuticals
SNDX
$1.41B
| $23.5M | 2.19% | 2,139,784 +375,000 | +21% | +$4.11M |
|
17
Replimune Group
REPL
$422M
| $19.7M | 1.84% | 1,975,209 -333,900 | -14% | -$3.33M |
|
|
FPRX
18
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $17.7M | 1.65% | 7,783,001 | – | – |
|
19
Phathom Pharmaceuticals
PHAT
$864M
| $17.5M | 1.63% | 676,561 -109,290 | -14% | -$2.82M |
|
|
CBIO
20
Crescent Biopharma, Inc. Common Stock
CBIO
$200M
| $16.8M | 1.56% | 7,361,801 | – | – |
|
21
Verastem
VSTM
$569M
| $16.7M | 1.56% | 6,328,994 | – | – |
|
22
Immunovant
IMVT
$2.56B
| $15.6M | 1.45% | 999,996 | – | – |
|
|
INFI
23
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $14.6M | 1.36% | 17,426,968 | – | – |
|
24
Mersana Therapeutics
MRSN
$36.5M
| $13.8M | 1.29% | 2,372,400 +1,191,847 | +101% | +$6.95M |
|
|
PVLA
25
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $13.4M | 1.25% | 5,872,762 +522,857 | +10% | +$1.19M |
|